Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus.
TCN-032 was discovered utilizing Theraclone’s I-STAR platform.The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo.The study expects to recruit aorund 40 volunteers at a single US site and will also provide pharmacokinetic and immunogenicity data.
Theraclone executive chairman and acting CEO Steven Gillis said I-STAR has repeatedly demonstrated an ability to identify natural human antibodies with exceptionally biologic activity and therapeutic potential.
